Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis.
J Antimicrob Chemother
; 53(2): 325-8, 2004 Feb.
Article
em En
| MEDLINE
| ID: mdl-14729733
ABSTRACT
OBJECTIVES:
Linezolid is a new oxazolidinone antibiotic with efficacy against a broad range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). In this study, we have determined the serum and sputum linezolid concentrations in adults with cystic fibrosis (CF) following oral drug administration.METHODS:
Eleven adult patients with CF were recruited. Subjects received 600 mg of linezolid orally every 12 h for a total of six doses. Serum and sputum levels were measured just before and at 2 h after the final dose of linezolid. A further serum level was measured at 4 h.RESULTS:
Ten adult patients completed the study. Mean (s.d.) serum linezolid concentrations were 2.3 mg/L (1.5) at 12 h following the fifth dose. At 2 and 4 h following the sixth dose, concentrations were 13.5 (4.3) and 8.1 (3.3). Mean (s.d.) linezolid sputum concentrations were 3.6 (2.1) and 17.4 (7.2) mg/L at 0 and 2 h following drug administration.CONCLUSIONS:
The oral administration of linezolid results in good sputum penetration in patients with CF. Mean levels exceed the required MIC for the treatment of MRSA for >80% of the dosing period for serum and the majority of the dosing period for sputum.
Buscar no Google
Coleções:
01-internacional
Temas:
Geral
Base de dados:
MEDLINE
Assunto principal:
Escarro
/
Oxazolidinonas
/
Fibrose Cística
/
Acetamidas
/
Antibacterianos
Tipo de estudo:
Observational_studies
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Antimicrob Chemother
Ano de publicação:
2004
Tipo de documento:
Article
País de afiliação:
Reino Unido